Ozempic, Wegovy Shortage Is Officially Over
The shortage of semaglutide injections (Ozempic, Wegovy) is over, the FDA announced on Friday. The agency, along with maker Novo Nordisk, confirmed that supply now meets or exceeds both the current and projected U.S. demand. The injectable formulation of the GLP-1 receptor agonist has been in shortage since August 2022 due to increased demand.
In this photo illustration, boxes of the diabetes drug Ozempic rest on a pharmacy counter on April 17, 2023 in Los Angeles, ...
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
The resolution could potentially restrict how telehealth programs offer cheaper versions known as compounded drugs ...
Leerink notes that the shortage of Novo Nordisk’s (NVO) semaglutide, marketed as Wegovy and Ozempic, has been resolved according to the FDA.
A randomized, placebo-controlled trial validates a side effect frequently observed by doctors and patients. A new study from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback